PROSTVAC™ paper published in Journal of Clinical Oncology
26 January 2010
Download pdf
Not for release, publication or
distribution, directly or indirectly in or into Australia, Canada,
Japan or the United States
This announcement does not constitute or
form part of an offer to sell or the solicitation of an offer to
buy the securities of Bavarian Nordic A/S (the "Securities") in
Australia, Canada, Japan or the United States or in any other
jurisdiction. The Securities may not be offered or sold in the
United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended. The issuer of
the Securities has not registered, and does not intend to register,
any portion of the Offering in the United States or in any
jurisdiction outside Denmark and the United Kingdom, and does not
intend to conduct a public offering of the Securities in the United
States or in any jurisdiction outside Denmark and the United
Kingdom. Copies of this announcement are not being made and may not
be distributed or sent into Australia, Canada, Japan or the United
States.
Kvistgård, Denmark, January 26, 2010 -
Bavarian Nordic A/S (OMX: BAVA) announced today that a
PROSTVAC™ paper has been published in the peer-reviewed
Journal of Clinical Oncology (JCO), the official journal of ASCO
(American Society of Clinical Oncology).
As announced in the prospectus dated 8 January 2010 regarding
the ongoing rights issue, Bavarian Nordic submitted its article to
the journal in 2009 with the expected publication in the first half
of 2010.
The paper titled: "Overall Survival Analysis of a Phase II
Randomized Controlled Trial of a Poxviral-Based PSA-Targeted
Immunotherapy in Metastatic Castration-Resistant Prostate
Cancer" has been published ahead of print on JCO's
website:
http://jco.ascopubs.org/cgi/content/abstract/JCO.2009.25.0597v1
The paper is based on the previously reported Phase II study,
showing a significant longer median survival (8.5 months) in men
with advanced prostate cancer.
Anders Hedegaard, President & CEO of Bavarian Nordic said:
"We are delighted that our PROSTVAC™ data has been
accepted for publication in Journal of Clinical Oncology, one of
the most prominent peer-reviewed oncology journals. This is indeed
a major recognition of the scientific potential of the vaccine and
highly supports the further development and our ongoing
preparations for the Phase III trials with
PROSTVAC™."
About PROSTVAC™
PROSTVAC™ is a therapeutic vaccine moving into late stage
clinical development that has the potential to extend the lives of
people with advanced prostate cancer. Administered subcutaneously,
it induces a specific, targeted immune response that attacks
prostate cancer cells. Conventional chemotherapy currently used to
treat prostate cancer has limited survival rates and is often
associated with numerous side effects. In contrast, PROSTVAC™
has the potential to extend survival with improved quality of life.
PROSTVAC™ is being developed in collaboration with the
National Cancer Institute under a Cooperative Research and
Development Agreement with Bavarian Nordic's U.S.-based subsidiary,
BN ImmunoTherapeutics.
In clinical trials to date PROSTVAC™ and related PSA
containing poxviral vaccines have been investigated and optimised
in more than 500 patients for 10 years.
Contact:
Anders Hedegaard, President & CEO.
Phone: +45 23 20 30 64